-
The Food and Drug Administration (FDA) added a "black box" warning in 2004 to the contraceptive injection depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City; Medroxyprogesterone Acetate Injectable Suspension USP, Teva Pharmaceuticals USA, North Wales, PA) advising that prolonged use might result in bone mineral density loss.
-
Field test results of a integrated microfluidic-based diagnostic device indicate that the potential "lab-on-a-chip" might be able to perform complex laboratory assays in a simple, convenient manner.
-
This case-driven discussion of microscopic hematuria includes important guidelines, definitions, and reminders to aid the clinician in managing this common finding.
-
-
Two independent case-control studies investigating the risk of venous thromboembolism (VTE) in users of oral contraceptives (OC) containing 30 mcg of ethinyl estradiol and a progestin component of either drospirenone or levonorgestrel found that VTE risk was two to three times higher in those using a drospirenone pill.
-
The concept that "term" pregnancy applies to any pregnancy extending past 36 completed weeks has been recently strongly challenged.
-
There are at least six different commonly used chemotherapeutic regimens in practice to treat patients with low-risk gestational trophoblastic neoplasia (GTN) with no consensus or previous formal evaluation as to which may be best.
-
New research indicates that early initiation of antiretroviral treatment in people infected with HIV prevents them from transmitting the virus to their partners.
-
Findings from a new analysis indicate that women pay a higher percentage out of pocket when it comes to oral contraceptive (OC) expenditures.
-
Research indicates that while many young women might initiate vaccination for human papillomavirus (HPV), they do not complete the three-injection course of treatment.
